Results 71 to 80 of about 1,925 (192)

β‐Lactamase‐Producing Haemophilus influenzae Pneumonia in a 1‐Month‐Old Infant With Respiratory Syncytial Virus Bronchiolitis

Journal of General and Family Medicine, Volume 27, Issue 3, May 2026.
Kazumasa Zensho, Naoki Nojima, Ryoma Hino, Naohi Isse   +3 more
wiley   +1 more source

Exacerbations and Management of Asthma in Viral Lower Respiratory Tract Infections: The Significance of Immunoglobulin E

Immunity, Inflammation and Disease, Volume 14, Issue 2, February 2026.
ABSTRACT Background Viral‐respiratory infections are the most prevalent illness among humans. A viral infection affecting lower respiratory tract infections (LRTI) is a critical health concern worldwide. The COVID‐19 pandemic has significantly impacted respiratory health, particularly in individuals with asthma.
Mandana Akhavan, Parastoo Yousefi, Alireza Tabibzadeh   +2 more
wiley   +1 more source

Sociodemographic Factors, Intent-Uptake Disparities, and Nirsevimab Availability in Infant RSV Immunoprophylaxis

Pediatric Reports
Background/Objectives: Respiratory syncytial virus (RSV) is the most common cause of bronchiolitis and infant hospitalization in the US. RSV prevention evolved in 2023 as nirsevimab and maternal RSV pre-fusion vaccine became available for healthy ...
Brody J. Lipsett, Benjamin N. Fogel, Katherine E. Shedlock, Ian M. Paul, Eric W. Schaefer, Ruth E. Gardner, Leah D. Kaye, Steven D. Hicks   +7 more
doaj   +1 more source

Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP)

, 2023
Introduction: Nirsevimab, a monoclonal antibody for the prevention of disease caused by respiratory syncytial virus (RSV), has recently been approved for use in Europe and Spain.
Ana Belén Jiménez, Frago, Susana, Rodrigo, Carlos, Llorente Romano, Marta, José Rumbao, Rumbao, José, Pérez, Carlos, Carlos Pérez, Laura Francisco, Calvo, Cristina, Cruz-Cañete, Marta, Llorente, Marta, Carlos Rodrigo, Marta Llorente, Marta Cruz-Cañete, Et al., Cristina Calvo, Montesdeoca, Abián, Launes, Cristian, Tagarro García, Alfredo, Abián Montesdeoca, Cruz Cañete, Marta, Cristian Launes, Otheo, Enrique, Susana Frago, Jiménez, Ana Belén, Francisco, Laura, Enrique Otheo, Tagarro, Alfredo, José Antonio Couceiro, Couceiro, José Antonio, Alfredo Tagarro   +31 more
core   +1 more source

Population Pharmacokinetics of Nirsevimab in Preterm and Term Infants

The Journal of Clinical Pharmacology
AbstractNirsevimab, a monoclonal antibody with an extended half‐life, is approved for the prevention of respiratory syncytial virus (RSV) disease in all infants in Canada, the EU, Great Britain, and the USA. A population pharmacokinetics (PK) model was built to describe the PK of nirsevimab in preterm and term infants, and to evaluate the influence of ...
Lindsay Clegg, Ed Freshwater, Amanda Leach, Tonya Villafana, Ulrika Wählby Hamrén   +4 more
openaire   +2 more sources

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source

Efficacy of nirsevimab for the prevention of RSV disease in infants: A systematic review, meta-analysis of randomized controlled trials, and global perspectives on recommendations and unmet needs

Pediatrics and Neonatology
Background: Respiratory syncytial virus (RSV) is a major cause of infant hospitalizations, with limited prophylactic options historically available.
Hsin-Chweng Lien, Chi-Hone Lien, Tzu-Yu Liu, Shun-Long Weng, Yu-Lin Tai, Ya-Ning Huang, Hsin Chi, Nan-Chang Chiu, Chun-Yan Yeung, Chien-Yu Lin   +9 more
doaj   +1 more source

Single-dose nirsevimab prevents RSV infection [PDF]

The Journal of Pediatrics, 2021
Shabir A, Madhi, Eric A F, Simões
openaire   +2 more sources

Changes in Respiratory Syncytial Virus‐Associated Hospitalisations Epidemiology After Nirsevimab Introduction in Lyon, France

International audienceBackground Respiratory Syncytial Virus (RSV) is a major health concern, particularly for infants. In France, Nirsevimab, a long‐acting monoclonal antibody to prevent RSV‐associated lower respiratory tract infections (LRTI) was ...
Ploin, Dominique, Butin, Marine, Horvat, Côme, Javouhey, Etienne, Hassenboehler, Juliette, Casalegno, Jean‐sebastien, Gillet, Yves, Plaisant, Franck, Ragouilliaux, Corinne, Nunes, Marta C., Chauvel, Cécile, Chakra, Claire Nour Abou   +11 more
core   +1 more source

Safety and Efficacy of Nirsevimab in a Universal Prevention Program of Respiratory Syncytial Virus Bronchiolitis in Newborns and Infants in the First Year of Life in the Valle d’Aosta Region, Italy, in the 2023–2024 Epidemic Season

Vaccines
Respiratory syncytial virus (RSV) bronchiolitis remains a significant global health burden, particularly in newborns and infants during their first year of life.
Alessandra Consolati, Mariapaola Farinelli, Paolo Serravalle, Christine Rollandin, Laura Apprato, Susanna Esposito, Salvatore Bongiorno   +6 more
doaj   +1 more source